Welcome to our dedicated page for Myriad Genetics news (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Myriad Genetics Inc. reports developments in molecular diagnostic testing and precision medicine, with recurring updates on tests that assess disease risk, disease progression, and treatment selection across medical specialties. Company news commonly covers the Cancer Care Continuum, Prenatal Health, and Mental Health businesses, including test volume trends, average revenue per test, earnings results, and financial guidance.
Updates also address Myriad's oncology diagnostics and research programs, including MyChoice CDx, Precise MRD, Prolaris, hereditary cancer testing, GeneSight, and prenatal testing products. News themes include companion diagnostic approvals, clinical data presentations, commercial launches, collaborations, and investor healthcare conference participation.
Myriad Genetics (NASDAQ: MYGN) welcomes Palmetto GBA's final local coverage determination (LCD) for pharmacogenomic (PGx) testing, allowing broad coverage for psychiatric conditions. The LCD covers both single-gene and multi-gene tests but notes limited support for combinatorial tests. President Mark S. Verratti expresses optimism for the GeneSight Psychotropic test's coverage under this LCD. Clinical studies indicate improved outcomes for patients informed by GeneSight compared to standard treatment. This decision responds to increased mental health issues during the COVID-19 pandemic.
Myriad Genetics (NASDAQ: MYGN) announced a new study published in Psychiatry Research, showcasing the superiority of the GeneSight® Psychotropic test in predicting citalopram and escitalopram blood levels over single-gene tests. The study assessed 191 patients, demonstrating that GeneSight identifies more patients with significant gene-drug interactions, which might be missed by traditional methods.
Myriad Genetics (NASDAQ: MYGN) announced a prospective study showing that the EndoPredict test can predict responses to neoadjuvant therapy in ER+, HER2- early-stage breast cancer patients. Published in the European Journal of Cancer, the study involved 217 patients, demonstrating that 26.4% of those with high EndoPredict scores had a favorable tumor response to neoadjuvant chemotherapy, while all with low scores had poor responses. The test aims to aid personalized treatment decisions and enhance future clinical trial designs.
Myriad Genetics, Inc. (NASDAQ: MYGN) has elected Daniel K. Spiegelman to its Board of Directors, expanding the board to nine members. Spiegelman brings over 30 years of experience in biotechnology, having served as CFO at BioMarin Pharmaceuticals. He will also join the audit committee. The company also announced that John T. Henderson, M.D., a board member since 2004 and former chair, will retire at the Annual Meeting in December 2020. Myriad Genetics focuses on advancing molecular diagnostics and precision medicine, enhancing its product portfolio and revenue streams.
Myriad Genetics (NASDAQ: MYGN) announced FDA approval for its BRACAnalysis CDx test, a companion diagnostic for identifying men with metastatic castration-resistant prostate cancer (mCRPC) eligible for Lynparza (olaparib) treatment. This marks the seventh regulatory approval for the test, enhancing treatment options for patients with BRCA1/BRCA2 mutations. The PROfound trial demonstrated significant improvement in progression-free survival for patients treated with Lynparza compared to standard therapies. Myriad aims to improve patient outcomes through precision medicine.
Myriad Genetics (MYGN) announced FDA approval for its myChoice CDx test, a companion diagnostic for identifying advanced ovarian cancer patients with homologous recombination deficiency (HRD) who are eligible for first-line maintenance treatment with Lynparza (olaparib) and bevacizumab. The approval enhances precision medicine, potentially benefiting one in two women with HRD-positive ovarian cancer. Myriad's collaboration with AstraZeneca since 2007 continues to foster advancements in cancer diagnostics.